SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today announced that Dr. Nassim Usman, Catalyst's President and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City.
|Rodman & Renshaw 17th Annual Global Investment Conference|
|Date:||Wednesday, September 9|
|Time:||5:30pm Eastern Time|
|Location:||St. Regis Hotel, Astor Suite A (2nd Floor)|
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst's most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst's lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com.
CONTACT: Investors: Fletcher Payne, CFO Catalyst Biosciences, Inc. 650-871-0761 firstname.lastname@example.org Media: Denise Powell Red House Consulting, LLC 510-703-9491 email@example.comSource:Catalyst Biosciences, Inc.